Compare ACADIA Pharmaceuticals Inc. (ACAD) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs CarMax, Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.46 (market cap $5.07B), while CarMax, Inc trades at $58.24 (market cap $8.26B). The key difference: CarMax, Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | KMX | |
|---|---|---|
Market Cap | $5.07B | $8.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.41 | $62.17 |
52-Week Low | $20.06 | $30.88 |
Enterprise Value | $4.19B | $26.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
CarMax (KMX) trades at $58.20, showing modest near-term weakness with a 0.99% daily decline. The stock maintains a bullish technical stance with strong moving average support and trades near key support at $58. Fundamentally, the company reported Q1 2026 earnings beat with $0.34 EPS versus $0.23 expected, though revenue trends show slight contraction from $26.4B in 2025 to projected $26.3B in 2026. Recent positive developments include AI partnership enhancements and strong institutional recognition.
CarMax presents a mixed investment case with technical strength offset by fundamental challenges. The bullish moving average configuration and recent earnings beats provide near-term support, but declining revenue trends and thin 0.84% net margin limit upside potential. Key risks include ongoing fiduciary investigations and competitive pressure in the used car market. Analyst consensus remains cautious with 68.6% hold ratings and $53.09 price target below current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
